Hillsdale Investment Management Inc. Has $4.25 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Hillsdale Investment Management Inc. lifted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 8.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 145,400 shares of the company’s stock after purchasing an additional 11,400 shares during the period. Hillsdale Investment Management Inc. owned 0.31% of Pacira BioSciences worth $4,249,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. ICA Group Wealth Management LLC acquired a new position in shares of Pacira BioSciences during the fourth quarter worth $30,000. Quadrant Capital Group LLC raised its stake in Pacira BioSciences by 61.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock worth $78,000 after buying an additional 885 shares during the last quarter. Cape Investment Advisory Inc. bought a new position in Pacira BioSciences during the fourth quarter worth $97,000. SG Americas Securities LLC bought a new position in Pacira BioSciences during the first quarter worth $106,000. Finally, Quest Partners LLC bought a new position in Pacira BioSciences during the fourth quarter worth $125,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insider Buying and Selling

In other news, insider Jonathan Slonin sold 2,836 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total value of $80,117.00. Following the transaction, the insider now owns 95,557 shares of the company’s stock, valued at approximately $2,699,485.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Jonathan Slonin sold 2,836 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total value of $80,117.00. Following the transaction, the insider now owns 95,557 shares of the company’s stock, valued at approximately $2,699,485.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Lauren Riker sold 3,970 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $28.72, for a total transaction of $114,018.40. Following the completion of the transaction, the senior vice president now directly owns 38,075 shares in the company, valued at approximately $1,093,514. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,150 shares of company stock valued at $602,170. Company insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PCRX shares. HC Wainwright reissued a “buy” rating and set a $57.00 target price on shares of Pacira BioSciences in a research note on Tuesday, July 2nd. Needham & Company LLC reissued a “buy” rating and set a $43.00 target price on shares of Pacira BioSciences in a research note on Tuesday, July 2nd. Barclays downgraded shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 price target on shares of Pacira BioSciences in a research note on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of “Moderate Buy” and a consensus price target of $46.10.

Pacira BioSciences Stock Up 4.3 %

Pacira BioSciences stock traded up $0.84 during midday trading on Monday, hitting $20.21. 1,166,389 shares of the stock were exchanged, compared to its average volume of 747,600. The business’s 50-day moving average price is $26.88 and its 200-day moving average price is $28.62. The company has a quick ratio of 4.78, a current ratio of 5.81 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $940.78 million, a price-to-earnings ratio of 14.13 and a beta of 0.88. Pacira BioSciences, Inc. has a 52-week low of $19.34 and a 52-week high of $40.16.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The firm had revenue of $167.12 million for the quarter, compared to the consensus estimate of $165.43 million. Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. On average, research analysts expect that Pacira BioSciences, Inc. will post 2.13 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.